Key Inclusion Criteria:

   - Documented diagnosis of B-cell CLL, according to International Workshop on Chronic
   Lymphocytic Leukemia 2008

   - Presence of 17p deletion in CLL cells as demonstrated by fluorescence in-situ
   hybridization (FISH) testing

   - No prior therapy for CLL other than corticosteroids for disease complications

   - CLL that warrants treatment

   - Presence of measurable lymphadenopathy

   - Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Key Exclusion Criteria:

   - Known histological transformation from CLL to an aggressive lymphoma (ie, Richter
   transformation)

   - Known presence of myelodysplastic syndrome

   - History of a non-CLL malignancy except for the following:

      - the malignancy has been in remission without treatment for ≥ 5 years prior to
      enrollment, or

      - carcinoma in situ of the cervix, or

      - adequately treated basal or squamous cell skin cancer or other localized
      non-melanoma skin cancer, or

      - asymptomatic prostate cancer without known metastatic disease and with no current
      requirement for therapy or requiring only hormonal therapy and with normal
      prostate specific antigen for ≥ 1 year prior to enrollment, or

      - ductal carcinoma in situ (DCIS) of the breast treated with lumpectomy alone, or

      - other adequately treated Stage 1 or 2 cancer currently in complete remission

   - Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of
   enrollment

   - Ongoing liver injury

   - History of noninfectious pneumonitis

   - Ongoing inflammatory bowel disease

   - History of prior allogeneic bone marrow progenitor cell or solid organ transplantation

   - Ongoing immunosuppressive therapy other than corticosteroids

   - Received last dose of study drug on another therapeutic clinical trial within 30 days
   prior to enrollment

   - Prior or ongoing clinically significant illness, medical condition, surgical history,
   physical finding, electrocardiogram (ECG) finding, or laboratory abnormality

Note: Other protocol defined Inclusion/Exclusion criteria may apply.